U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H53NO5
Molecular Weight 495.7348
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ORLISTAT

SMILES

CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

InChI

InChIKey=AHLBNYSZXLDEJQ-FWEHEUNISA-N
InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

HIDE SMILES / InChI
Molecular Formula C29H53NO5
Molecular Weight 495.7348
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.fda.gov/downloads/UCM205349.pdf https://www.ncbi.nlm.nih.gov/pubmed/9225172 https://www.ncbi.nlm.nih.gov/pubmed/16956313

Orlistat or tetrahydrolipstatin (Xenical, Hoffmann-La Roche) is a saturated derivative of lipstatin originally isolated from Streptomyces toxytricini. Orlistat (Xenical, Hoffmann-La Roche) is a powerful inhibitor of gastrointestinal lipase and as such, reduces fat absorption. Orlistat acts by binding covalently to the serine residue of the active site of gastric and pancreatic lipases. When administered with fat-containing foods, orlistat partially inhibits hydrolysis of triglycerides, thus reducing the subsequent absorption of monoaclglycerides and free fatty acids. Unlike other weight-reducing drugs it is minimally absorbed and has no effects in the CNS. Xenical is indicated for obesity management including weight loss and weight maintenance when used in conjunction witha reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥ 30 kg/m2 or ≥ 27 kg/m2 in the presence of other risk factors (eg, hypertension, diabetes, dyslipidemia). In addition to its well established efficacy in achieving modest weight loss, orlistat has been shown to improve glycaemic parameters in obese adults with type 2 diabetes mellitus as well as some features of the metabolic syndrome.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: Orlistat is minimally absorbed and has no effects in the CNS

Originator

Hoffman-La Roche
134
Curator's Comment: # Hoffmann-La Roche & Co., Ltd.

Approval Year

1999
174
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Inhibitor
8297
 100.0 nM [Ki]
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
XENICAL

Approved Use

XENICAL orlistat capsule is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 in the presence of other risk factors (eg, hypertension, diabetes, dyslipidemia).

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
150 ng × eq/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8973989
360 mg single, oral
dose: 360 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ORLISTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
907 ng × eq × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8973989
360 mg single, oral
dose: 360 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ORLISTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020766s029lbl.pdf
ORLISTAT plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020766s029lbl.pdf
ORLISTAT plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5160 mg single, oral
Overdose
Dose: 5160 mg
Route: oral
Route: single
Dose: 5160 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19763670
healthy, 28 months
n = 1
Health Status: healthy
Age Group: 28 months
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19763670
Sources:
https://pubmed.ncbi.nlm.nih.gov/19763670
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
healthy, 51 years (range: 30-65 year)
n = 33
Health Status: healthy
Age Group: 51 years (range: 30-65 year)
Sex: M+F
Population Size: 33
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
Disc. AE: Fatigue...
AEs leading to
discontinuation/dose reduction:
Fatigue (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
120 mg 3 times / day steady, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: steady
Dose: 120 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
healthy, 52 years (range: 30-65 year)
n = 35
Health Status: healthy
Age Group: 52 years (range: 30-65 year)
Sex: M+F
Population Size: 35
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
Disc. AE: Rectal oily spotting, Flatus...
AEs leading to
discontinuation/dose reduction:
Rectal oily spotting (1 patient)
Flatus (1 patient)
Abdominal pain (1 patient)
Painful defaecation (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
180 mg 1 times / day steady, oral
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
healthy, 53 years (range: 30-65 year)
n = 35
Health Status: healthy
Age Group: 53 years (range: 30-65 year)
Sex: M+F
Population Size: 35
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
Disc. AE: Loose stools, Myocardial infarction...
AEs leading to
discontinuation/dose reduction:
Loose stools (2 patients)
Myocardial infarction (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
60 mg 3 times / day steady, oral
Recommended
Dose: 60 mg, 3 times / day
Route: oral
Route: steady
Dose: 60 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
healthy, 54 years
n = 1
Health Status: healthy
Age Group: 54 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
Disc. AE: Fatigue, Weakness generalized...
AEs leading to
discontinuation/dose reduction:
Fatigue
Weakness generalized
Nausea
Jaundice
Pruritus
Hepatic failure
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
healthy, 55 years (range: 30-65 year)
n = 33
Health Status: healthy
Age Group: 55 years (range: 30-65 year)
Sex: M+F
Population Size: 33
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
Disc. AE: Loose stools...
AEs leading to
discontinuation/dose reduction:
Loose stools (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
120 mg 3 times / day steady, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: steady
Dose: 120 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20766lbl.pdf
healthy, adult
n = 1913
Health Status: healthy
Age Group: adult
Population Size: 1913
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20766lbl.pdf
Disc. AE: Gastrointestinal symptom NOS...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal symptom NOS (8.8%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20766lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Fatigue 1 patient
Disc. AE
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
healthy, 51 years (range: 30-65 year)
n = 33
Health Status: healthy
Age Group: 51 years (range: 30-65 year)
Sex: M+F
Population Size: 33
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
Abdominal pain 1 patient
Disc. AE
120 mg 3 times / day steady, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: steady
Dose: 120 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
healthy, 52 years (range: 30-65 year)
n = 35
Health Status: healthy
Age Group: 52 years (range: 30-65 year)
Sex: M+F
Population Size: 35
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
Flatus 1 patient
Disc. AE
120 mg 3 times / day steady, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: steady
Dose: 120 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
healthy, 52 years (range: 30-65 year)
n = 35
Health Status: healthy
Age Group: 52 years (range: 30-65 year)
Sex: M+F
Population Size: 35
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
Painful defaecation 1 patient
Disc. AE
120 mg 3 times / day steady, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: steady
Dose: 120 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
healthy, 52 years (range: 30-65 year)
n = 35
Health Status: healthy
Age Group: 52 years (range: 30-65 year)
Sex: M+F
Population Size: 35
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
Rectal oily spotting 1 patient
Disc. AE
120 mg 3 times / day steady, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: steady
Dose: 120 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
healthy, 52 years (range: 30-65 year)
n = 35
Health Status: healthy
Age Group: 52 years (range: 30-65 year)
Sex: M+F
Population Size: 35
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
Myocardial infarction 1 patient
Disc. AE
180 mg 1 times / day steady, oral
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
healthy, 53 years (range: 30-65 year)
n = 35
Health Status: healthy
Age Group: 53 years (range: 30-65 year)
Sex: M+F
Population Size: 35
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
Loose stools 2 patients
Disc. AE
180 mg 1 times / day steady, oral
Dose: 180 mg, 1 times / day
Route: oral
Route: steady
Dose: 180 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
healthy, 53 years (range: 30-65 year)
n = 35
Health Status: healthy
Age Group: 53 years (range: 30-65 year)
Sex: M+F
Population Size: 35
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
Fatigue Disc. AE
60 mg 3 times / day steady, oral
Recommended
Dose: 60 mg, 3 times / day
Route: oral
Route: steady
Dose: 60 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
healthy, 54 years
n = 1
Health Status: healthy
Age Group: 54 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
Hepatic failure Disc. AE
60 mg 3 times / day steady, oral
Recommended
Dose: 60 mg, 3 times / day
Route: oral
Route: steady
Dose: 60 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
healthy, 54 years
n = 1
Health Status: healthy
Age Group: 54 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
Jaundice Disc. AE
60 mg 3 times / day steady, oral
Recommended
Dose: 60 mg, 3 times / day
Route: oral
Route: steady
Dose: 60 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
healthy, 54 years
n = 1
Health Status: healthy
Age Group: 54 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
Nausea Disc. AE
60 mg 3 times / day steady, oral
Recommended
Dose: 60 mg, 3 times / day
Route: oral
Route: steady
Dose: 60 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
healthy, 54 years
n = 1
Health Status: healthy
Age Group: 54 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
Pruritus Disc. AE
60 mg 3 times / day steady, oral
Recommended
Dose: 60 mg, 3 times / day
Route: oral
Route: steady
Dose: 60 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
healthy, 54 years
n = 1
Health Status: healthy
Age Group: 54 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
Weakness generalized Disc. AE
60 mg 3 times / day steady, oral
Recommended
Dose: 60 mg, 3 times / day
Route: oral
Route: steady
Dose: 60 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
healthy, 54 years
n = 1
Health Status: healthy
Age Group: 54 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25826164
Loose stools 2 patients
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
healthy, 55 years (range: 30-65 year)
n = 33
Health Status: healthy
Age Group: 55 years (range: 30-65 year)
Sex: M+F
Population Size: 33
Sources:
https://pubmed.ncbi.nlm.nih.gov/7957533
Gastrointestinal symptom NOS 8.8%
Disc. AE
120 mg 3 times / day steady, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: steady
Dose: 120 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20766lbl.pdf
healthy, adult
n = 1913
Health Status: healthy
Age Group: adult
Population Size: 1913
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20766lbl.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:94686
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:94686
ChemicalBook
CB2431985
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2431985
MolPort
MolPort-005-938-035
https://www.molport.com/shop/molecule-link/MolPort-005-938-035
Selleck Chemicals
Orlistat(Alli)
http://www.selleckchem.com/products/Orlistat(Alli).html
ZINC
ZINC000008214635
http://zinc15.docking.org/substances/ZINC000008214635
eMolecules
593023
https://www.emolecules.com/cgi-bin/more?vid=593023
PubMed

PubMed

TitleDatePubMed
Depression induced by orlistat (Xenical).
2000 Feb
Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.
2001
Pharmacological treatment of obesity in paediatric patients.
2001
Obesity and free fatty acids: double trouble.
2001 Apr
The role of orlistat in weight management.
2001 Apr
Evidence for specific ceramidase present in the intestinal contents of rats and humans.
2001 Aug
Bulimia nervosa and misuse of orlistat: two case reports.
2001 Dec
Orlistat associated subacute hepatic failure.
2001 Jan
Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers.
2001 Jul
Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
2001 Jun
Diabetic ketoacidosis associated with orlistat treatment.
2001 Mar
Obesity drug endorsed by NICE.
2001 Mar 17
Surface behaviour of bile salts and tetrahydrolipstatin at air/water and oil/water interfaces.
2001 May
The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
2001 Nov
Lipoprotein lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent of scavenger receptor BI.
2001 Nov
Orlistat inhibits dietary cholesterol absorption.
2001 Oct
Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience.
2001 Oct
About orlistat.
2001 Sep
Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function.
2001 Sep
Weighing the options in the pharmacotherapy of obesity.
2001 Sep
Treating obesity: a new target for prevention of coronary heart disease.
2001 Summer
[Weight reduction. Antiobesity drug treatment in type-2 diabetics].
2002
[Orlistat. A treatment of limited value for obese persons].
2002 Apr
Roche turns to DM to boost patient compliance with its weight loss drug.
2002 Apr
Results of obesity treatment.
2002 Apr
The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity.
2002 Apr
Orlistat: its current status as an anti-obesity drug.
2002 Apr 12
Effects of lipoprotein lipase on uptake and transcytosis of low density lipoprotein (LDL) and LDL-associated alpha-tocopherol in a porcine in vitro blood-brain barrier model.
2002 Aug 9
Orlistat: a second look. At best, a minor adjunct to dietary measures.
2002 Feb
Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients.
2002 Feb
Are soft tissue composition of bone and non-bone pixels in spinal bone mineral measurements by DXA similar? Impact of weight loss.
2002 Jan
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
2002 Jan
Obesity.
2002 Jan
Usefulness of Orlistat in the treatment of severe hypertriglyceridemia.
2002 Jan 15
[Treatment in the community health centers in accordance with recommendations of the Medical Products Agency. Unsatisfactory weight reduction with orlistat].
2002 Jan 31
[Are drugs necessary in the treatment of obesity?].
2002 Jan-Feb
Constipation, polyuria, polydipsia, and edema associated with orlistat.
2002 Jul-Aug
Combining behavioral and pharmacological treatments for obesity.
2002 Jun
Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
2002 Jun
Additive gastrointestinal effects with concomitant use of olestra and orlistat.
2002 Jun
Demand, appropriateness and prescribing of 'lifestyle drugs': a consultation survey in general practice.
2002 Jun
[Anti-obesity drugs: sibutramine and orlistat].
2002 Mar 30
Orlistat in the treatment of Type 2 diabetes mellitus.
2002 May
Patents

Patents

04983746
2
08637700
2
JP2001172180A
3
JP2001220387A
1
JP2001509173A
1
JP2002511398A
12
JP2002522491A
1
JP2002522492A
1
JP2002541106A
98
JP2003500451A
2
JP2003509373A
3
JP2003511458A
17
JP2003518129A
11
JP2003518130A
14
JP2003521546A
1
JP2004346078A
1
JP2004505066A
1
JP2004505067A
1
JP2004536047A
24
JP2005531588A
8
JP2006520365A
2
JP2007501823A
1
JP2007501852A
1
JP2007509048A
1
JP2007514770A
75
JP2008120821A
1
JP2009073833A
1
JP2009108062A
1
JP2009108076A
1
JP2009173635A
1
JP2011528275A
455
JP3761783B2
1
JP3774118B2
1
JP4217017B2
1
JP4265911B2
1
JP4365554B2
22
JP4737836B2
1
JP4772264B2
1
JP4851546B2
1
JPH05194471A
1
JPH1066592A
1
JPH11255645A
1

Sample Use Guides

In Vivo Use Guide
The recommended dose of XENICAL (orlistat capsule) is one 120-mg capsule three times a day with each main meal containing fat (during or up to 1 hour after the meal).
Route of Administration: Oral
In Vitro Use Guide
Orlistat inhibited cell proliferation by 61 % in ECC-1 cells and 57 % in KLE cells at a dose of 500 μM
Substance Class Chemical
Created
by admin
on Sat Dec 16 04:54:52 GMT 2023
Edited
by admin
on Sat Dec 16 04:54:52 GMT 2023
Record UNII
95M8R751W8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ORLISTAT
EMA EPAR   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
ORLISTAT [USP-RS]
Common Name English
ORLISTAT [USP MONOGRAPH]
Common Name English
ORLISTAT [MART.]
Common Name English
Orlistat [WHO-DD]
Common Name English
RO-180647-002
Code English
XENICAL
Brand Name English
orlistat [INN]
Common Name English
RO-18-0647/002
Code English
RO 18-0647/002
Code English
L-LEUCINE, N-FORMYL-, 1-((3-HEXYL-4-OXO-2-OXETANYL)METHYL)DODECYL ESTER, (2S-(2.ALPHA.(R*),3.BETA.))-
Common Name English
ORLISTAT [JAN]
Common Name English
ALLI
Brand Name English
ORLISTAT [USAN]
Common Name English
ORLISTAT [VANDF]
Common Name English
N-FORMYL-L-LEUCINE, ESTER WITH (3S,4S)-3-HEXYL-4-((2S)-2-HYDROXYTRIDECYL)-2-OXETANONE
Common Name English
NSC-758881
Code English
ORLISTAT [ORANGE BOOK]
Common Name English
ORLISTAT [HSDB]
Common Name English
RO-180647002
Code English
ORLISTAT [EMA EPAR]
Common Name English
ORLISTAT [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000009916
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
WHO-ATC A08AB01
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
EMA ASSESSMENT REPORTS ALLI (AUTHORIZED: OBESITY)
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
NCI_THESAURUS C29715
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
EMA ASSESSMENT REPORTS XENICAL (AUTHORIZED: OBESITY)
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
NDF-RT N0000175591
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
WHO-VATC QA08AB01
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
LIVERTOX NBK548898
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
Code System Code Type Description
HSDB
7556
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
DRUG CENTRAL
1996
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
NSC
758881
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
NCI_THESAURUS
C29303
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
INN
6318
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
DAILYMED
95M8R751W8
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
EVMPD
SUB09460MIG
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
PUBCHEM
3034010
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
ChEMBL
CHEMBL175247
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
WIKIPEDIA
ORLISTAT
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
USAN
DD-13
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
SMS_ID
100000091440
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
IUPHAR
5277
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
MESH
C055122
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
CHEBI
94686
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
RS_ITEM_NUM
1478800
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID8023395
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
RXCUI
37925
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m8234
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY Merck Index
FDA UNII
95M8R751W8
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
CAS
96829-58-2
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
DRUG BANK
DB01083
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
LACTMED
Orlistat
Created by admin on Sat Dec 16 04:54:52 GMT 2023 , Edited by admin on Sat Dec 16 04:54:52 GMT 2023
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of ORLISTAT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PANCREATIC TRIACYLGLYCEROL LIPASE
TARGET -> INHIBITOR
IRREVERSIBLE INHIBITOR
Related Record Type Details
Structure of RO-61-0593
METABOLITE -> PARENT
URINE
Structure of 2-HEXYL-3,5-DIHYDROXYDECANEDIOIC ACID, (2S,3R,5S)-
METABOLITE -> PARENT
URINE
Structure of ORLISTAT OPEN RING (S,S)-ISOMER
METABOLITE -> PARENT
MAJOR
PLASMA
Structure of RO-61-0593 GLUCURONIDE
METABOLITE -> PARENT
MAJOR
URINE
Structure of 2-HEXYL-3,5-DIHYDROXYHEXADECANOIC ACID, (2S,3R,5S)-
METABOLITE -> PARENT
MAJOR
PLASMA
Related Record Type Details
Structure of 3-HEXYL-4-((R)-2-HYDROXYTRIDECYL)-2-OXETANONE, (3S,4S)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
Structure of Orlistat, (R,S,S,S)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of ORLISTAT HEXYL UNDECYL PYRANONE
IMPURITY -> PARENT
Structure of TRIPHENYLPHOSPHINE OXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-FORMYL-L-LEUCINE (3S,4R,6S)-3-HEXYL-2-OXO-6-UNDECYLTETRAHYDRO-2H-PYRAN-4-YL ESTER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of ORLISTAT HENICOSENYL LEUCINATE
IMPURITY -> PARENT
Structure of ORLISTAT OPEN RING EPIMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-FORMYLLEUCINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DIISOPROPYL HYDRAZODICARBOXYLATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
Structure of ORLISTAT OPEN RING AMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of ORLISTAT OPEN RING ((1R)-1-PHENYL)ETHYLAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of ISOLEUCINE ORLISTAT, L-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of ORLISTAT
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966